New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with
Keytruda ® (pembrolizumab)
Incyte’s IDO1 enzyme inhibitor in combination with Merck’s anti-PD-1 therapy is well-tolerated and
demonstrates durable clinical responses across multiple solid tumors
Incyte Corporation (Nasdaq:INCY) today announced the publication of new data from the ongoing ECHO-202 trial, evaluating
epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with Keytruda® (pembrolizumab), Merck’s anti-PD-1
therapy. Abstracts published online by the American Society of Clinical Oncology (ASCO) in advance of its annual meeting in
Chicago, Illinois, June 2-6, 2017 include ECHO-202 Phase 1/2 efficacy and safety data from the following cohorts: non-small cell
lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, squamous cell carcinoma of the head and neck (SCCHN),
triple-negative breast cancer (TNBC), and ovarian cancer (OVC). Pooled Phase 2 safety data across cohorts were also released
today.
“We are very pleased to share these new data for epacadostat in combination with pembrolizumab. The combination is
well-tolerated and preliminary efficacy outcomes for these cohorts demonstrate encouraging clinical activity, both within and
across tumor types, which compares favorably to contemporary data in the second-line setting. These data, including updated data
which will be presented at ASCO next month, supported the recently-announced progression of the epacadostat and pembrolizumab
combination into pivotal trials in NSCLC, RCC, bladder cancer and SCCHN,” said Steven Stein, M.D., Chief Medical Officer,
Incyte.
ECHO-202 abstract data for the tumor types entering Phase 3 (data cut as of October 29, 2016) include:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
n/N
(%)
|
|
|
NSCLC |
|
|
|
UC |
|
|
|
SCCHN |
|
|
|
RCC |
|
|
All pts |
|
|
|
0-2 prior lines of
therapy for advanced
disease
|
|
|
|
All pts |
|
|
|
Prior Lines of
Treatment
|
|
|
|
All pts |
|
|
|
Prior Lines of
Treatment
|
|
|
|
All pts |
|
|
|
Prior Lines of
Treatment
|
|
|
Total |
|
|
|
TPS ≥50% |
|
|
|
TPS <50% |
|
|
|
Total |
|
|
|
0-1 |
|
|
|
Total |
|
|
|
1-2 |
|
|
|
≥3 |
|
|
|
Total |
|
|
|
0-1 |
|
|
|
≥2 |
ORR |
|
|
14/40
(35) |
|
|
|
3/7
(43) |
|
|
|
6/17
(35) |
|
|
|
13/37
(35) |
|
|
|
10/27
(37) |
|
|
|
11/36
(31)
|
|
|
|
10/29
(34)
|
|
|
|
1/7
(14)
|
|
|
|
9/30
(30)
|
|
|
|
9/19
(47)
|
|
|
|
0/11
(0) |
|
|
all PR |
|
|
|
all PR |
|
|
|
all PR |
|
|
|
all PR |
|
|
|
all PR |
|
|
|
2 CR,
9 PR |
|
|
|
2 CR,
8 PR |
|
|
|
1 PR |
|
|
|
1 CR,
8 PR |
|
|
|
1 CR,
8 PR |
|
|
|
- |
DCR |
|
|
24/40
(60) |
|
|
|
4/7
(57) |
|
|
|
9/17
(53) |
|
|
|
21/37
(57) |
|
|
|
17/27
(63) |
|
|
|
21/36
(58) |
|
|
|
18/29
(62)
|
|
|
|
3/7
(43) |
|
|
|
15/30
(50) |
|
|
|
11/19
(58) |
|
|
|
4/11
(36) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DoR |
|
|
12/14 responses ongoing
range 1+ - 519 days
|
|
|
|
12/13 responses ongoing
range 1+ - 652+ days
|
|
|
|
9/11 responses ongoing
range 1+ - 563+ days
|
|
|
|
9/9 responses ongoing
range 1+ - 372+ days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In a pooled analysis evaluating 244 patients in the ECHO-202 Phase 2 safety population (abstract #3012), treatment-related
adverse events (TRAEs) that occurred in ≥5 percent of patients, included fatigue (23 percent); rash (16 percent); diarrhea and
nausea (7 percent each); increased alanine aminotransferase, increased aspartate aminotransferase, and pruritus (6 percent each);
and pyrexia (5 percent). A total of 37 patients (15 percent) experienced Grade ≥3 TRAEs; the most common of which were increased
lipase (asymptomatic) and rash (3 percent each). TRAEs led to discontinuation of treatment in 3 percent of study patients.
These abstracts, including data for TNBC and OVC (abstract #1103), were made available today on the ASCO website at www.asco.org.
About ECHO-202 (KEYNOTE-037)
The ECHO-202 study (NCT02178722) is evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 inhibitor, in
combination with pembrolizumab. Patients previously treated with anti-PD-1 or anti-CTLA-4 therapies were excluded from this trial.
Enrollment is complete for the Phase 1 dose escalation (epacadostat 25, 50, 100 mg BID + pembrolizumab 2 mg/kg IV Q3W and
epacadostat 300 mg BID + pembrolizumab 200 mg IV Q3W) and Phase 1 dose expansion (epacadostat 50, 100, and 300 mg BID +
pembrolizumab 200 mg IV Q3W) portions of the trial. For more information about ECHO-202, visit https://clinicaltrials.gov/ct2/show/NCT02178722.
About ECHO
The ECHO clinical trial program was established to investigate the efficacy and safety of epacadostat as a core component of
combination therapy in oncology. Ongoing Phase 1 and Phase 2 studies evaluating epacadostat in combination with PD-1 and PD-L1
inhibitors collectively plan to enroll over 900 patients in a broad range of solid tumor types as well as hematological
malignancies. ECHO-301 (NCT02752074), a Phase 3 randomized, double-blind, placebo-controlled study investigating KEYTRUDA in
combination with epacadostat or placebo for the treatment of patients with unresectable or metastatic melanoma, is also underway.
For more information about the ECHO clinical trial program, visit www.ECHOClinicalTrials.com.
About Epacadostat (INCB024360)
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key immunosuppressive enzyme that modulates the anti-tumor immune response by
promoting regulatory T cell generation and blocking effector T cell activation, thereby facilitating tumor growth by allowing
cancer cells to avoid immune surveillance. Epacadostat is a first-in-class, highly potent and selective oral inhibitor of the IDO1
enzyme that regulates the tumor immune microenvironment, thereby restoring effective anti-tumor immune responses. In single-arm
studies, the combination of epacadostat and immune checkpoint inhibitors has shown proof-of-concept in patients with unresectable
or metastatic melanoma. In these studies, epacadostat combined with the CTLA-4 inhibitor ipilimumab or the PD-1 inhibitor
pembrolizumab improved response rates compared with studies of the immune checkpoint inhibitors alone.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements
regarding the presentation and discussion of data regarding the Company’s ECHO-202 study and the planned pivotal trials of
epacadostat in combination with pembrolizumab, contain predictions, estimates and other forward-looking statements. These
forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause
actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the
Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated
with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and
technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange
Commission, including its Form 10-Q for the quarter ended March 31, 2017. Incyte disclaims any intent or obligation to update these
forward-looking statements.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. KEYTRUDA
is marketed by Merck (known as MSD outside the United States and Canada).
Incyte Corporation
Media
Catalina Loveman, +1 302-498-6171
cloveman@incyte.com
or
Investors
Michael Booth, DPhil, +1 302-498-5914
mbooth@incyte.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517006345/en/